100s of titles, one news app for just $10 a month.
Dive Deeper:
Workiva's Return On Capital Employed Insights
Benzinga Pro data, Workiva (NYSE:WK) reported Q1 sales of $129.67 million. Earnings fell to a loss of $18.49 million, resulting…
MPLX's Return On Capital Employed Insights
Pulled from Benzinga Pro data, MPLX (NYSE:MPLX) posted Q1 earnings of $833.00 million, an increase from Q4 of 0.6%. Sales…
Triton International's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Triton International (NYSE:TRTN) posted Q1 earnings of $194.26 million, an increase from Q4 of 2.0%.…
Apollo Endosurgery's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Apollo Endosurgery's (NASDAQ:APEN) reported sales totaled $16.66 million. Despite a 19.14% increase…
One subscription that gives you access to news from hundreds of sites
Kymera Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million,…
Esperion Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but…
Get all your news in one place
Latest Business news:
Asian stocks up after Wall Street dip on China's Covid-bruised data
Hong Kong (AFP) - Asian stocks rose Tuesday despite a lukewarm lead from Wall Street after weak Chinese economic data…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Musk: Twitter deal at lower price "not out of the question"
Musk has continued to express skepticism about the company's estimate of spam and fake accounts.
Netflix toys with live TV as sales slump
Would pouring more money into original content do anything to help Netflix's profits?
Michael 'Big Short' Burry Shorts Apple
Hedge fund investor Michael Burry bets against Apple.
Once a powerful symbol in Russia, McDonald's withdraws
Two months after the Berlin Wall fell, another powerful symbol opened its doors in the middle of Moscow: a gleaming…
From analysis to good news, read the world’s best news in one place
U.S. backs U.N. push to get Ukraine grain back to global market
The United States supports efforts by U.N. Secretary-General Antonio Guterres to get Ukrainian grain back into the international marketplace amid…
ASX rises despite economic worries, Wall Street struggles on recession risk
Mining and energy companies propped up the Australian share market on Tuesday, though worries about a global economic slowdown and…

CytoSorbents's Return On Capital Employed Insights

By Benzinga Insights

According to data from Benzinga Pro, during Q1, CytoSorbents's (NASDAQ:CTSO) reported sales totaled $8.69 million. Despite a 3.66% increase in earnings, the company posted a loss of $8.97 million. In Q4, CytoSorbents brought in $10.78 million in sales but lost $9.31 million in earnings.

Why Is ROCE Significant?

Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, CytoSorbents posted an ROCE of -0.16%.

It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows CytoSorbents is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For CytoSorbents, a negative ROCE ratio of -0.16% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

CytoSorbents reported Q1 earnings per share at $-0.21/share, which did not meet analyst predictions of $-0.12/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Workiva's Return On Capital Employed Insights
Benzinga Pro data, Workiva (NYSE:WK) reported Q1 sales of $129.67 million. Earnings fell to a loss of $18.49 million, resulting…
MPLX's Return On Capital Employed Insights
Pulled from Benzinga Pro data, MPLX (NYSE:MPLX) posted Q1 earnings of $833.00 million, an increase from Q4 of 0.6%. Sales…
Triton International's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Triton International (NYSE:TRTN) posted Q1 earnings of $194.26 million, an increase from Q4 of 2.0%.…
Apollo Endosurgery's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Apollo Endosurgery's (NASDAQ:APEN) reported sales totaled $16.66 million. Despite a 19.14% increase…
One subscription that gives you access to news from hundreds of sites
Kymera Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million,…
Esperion Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but…
Get all your news in one place